Navigation Links
Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
Date:12/22/2011

SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the completion of its public offering of 5,646,173 units.  Each unit consisted of one share of common stock and a warrant to purchase ten shares of common stock, at a price to the public of $1.45 per share of common stock and $1.449 per warrant to purchase each share of common stock, which together comprised the purchase price of $15.94 per unit.   Net proceeds, after underwriting discounts and commissions and estimated expenses, were approximately $86.9 million.  The underwriter does not have an option to purchase any additional units in this offering. Leerink Swann LLC acted as sole manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2009.  The offering was made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Orexigen® Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

 

 

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
2. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
4. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
7. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
8. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
11. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, the ... services since 1997, is changing the landscape of ... providing patients with pro-active, custom-made solutions. Recognizing the ... instant and affordable healthcare without walls, Visiomed has ... devices developed with healthcare professionals that is empowering ...
(Date:2/23/2017)... 23, 2017 ITL Limited, ( ASX: ITD ), an ... the half year ended 31 December 2016 compared with the previous ... can be viewed here . Highlights ... up 104%) Earnings per share of 2.2 cents ... $17.5m (Dec 2015: $15.7m; up 11%) Profit before ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: ... clinical attributes? How are they positioned in the Global Fibromyalgia market? ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... Prophecy concerning this present generation. Yisrayl makes an astounding statement when he says ... He explains that the Bible details the current times so plainly that anyone should ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, ... thought leadership , media relations, social media, content marketing and SEO, is ... powered through Act-On, an intuitive marketing automation platform. , Rosica will now offer ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Department of Justice jointly issued a letter to withdraw previous guidance ... with their gender identity. The guidance issued in May 2016 by the Obama ...
(Date:2/23/2017)... ... ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS Martin ... supporter of the event. , "We are pleased that KLS Martin is joining us ... ACPA President. "KLS Martin has a long track record of support of the American ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO ... the National Institute for Health and Care Excellence (NICE) framework. The ... National Health Service (NHS) to search, order and purchase medical and healthcare-related content ...
Breaking Medicine News(10 mins):